Leukemia & lymphomaHumansLeukemiaMyelogenousChronicBCR-ABL Positive
Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia.
Roberto Latagliata, Ida Carmosino, Ambra Di Veroli, Emilia Scalzulli, Claudia Ielo, Gioia De Angelis, Roberta Laureana, Cinzia De Gregoris, Maria Laura Bisegna, Giulio Trapè, Maurizio Martelli, Massimo Breccia
Published: 202610.1080/10428194.2025.2586816
Abstract
To assess the impact of imatinib compared to 2 G-TKIs on hemoglobin (Hb) in the long-lasting frontline treatment, 242 patients with chronic myeloid leukemia (CML) from 2 Centers still receiving frontline TKI after 5 years [186 (76.8%) imatinib and 56…
Preview only. Read the full abstract at the source